Pfizer's billion-dollar Celebrex patent loss has Mylan, Actavis revving up generics
13.03.2014 / Fierce Pharma
One of Pfizer's top-selling products is suddenly vulnerable to generic competition 18 months earlier than expected. A U.S. court nixed a key Celebrex patent, putting the pain drug up for a sales fight in May. And generics makers Mylan and Actavis are promising to launch their versions as soon as Pfizer's monopoly expires.